Director/PDMR Shareholding

hVIVO

02/06/2025 07:00

RNS Number : 9171K

hVIVO PLC

02 June 2025

 

                                                                                                       hVIVO plc

("hVIVO", the "Company" or the "Group")

 

CEO & CFO Share Purchase

 

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin 'Mo' Khan, Chief Executive Officer and Stephen Pinkerton, Chief Financial Officer, purchased shares in the Company as detailed below:

 

Director
No of shares purchased
Purchase Price
Resultant holding
Resultant holding as a % of the issued share capital
Yamin'Mo' Khan
1,100,000
8.9 pence
5,001,603
0.73%
Stephen Pinkerton
683,232*
8.76 pence
750,596*
0.11%

 

*343,232 of these shares were purchased/are held by Mrs Dolores Pinkerton, wife of Stephen Pinkerton

                               

Commenting, Dr Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "Friday's trading update clearly raised concerns for our shareholders, but we remain confident in the continued growth of human challenge trials and the overall prospects for hVIVO, and accordingly Stephen and I have increased our shareholdings in the Company to demonstrate our continued confidence in the growth prospects of the Group.

 

"We have our largest ever sales pipeline, including projects under discussion that would represent some of our biggest ever value contracts for human challenge trials, such as the world's first ever Phase 3 HCT. We have also successfully targeted a more diversified revenue base and we remain very excited about the growth prospects of our hLAB services as well as our new revenue streams from CRS's early phase clinical trial services and participant recruitment."

 

 

For further information please contact:

 

hVIVO plc
+44 (0)20 7756 1300
Yamin'Mo' Khan, Chief Executive Officer
Stephen Pinkerton, Chief Financial Officer
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
+44 (0)20 7220 0500
Geoff Nash, Callum Davidson,
 Trisyia Jamaludin, Harriet Ward
Nigel Birks - Life Science Specialist Sales
Louise Talbot - Sales
Peel Hunt LLP (Joint Broker)
+44 (0)20 7418 8900
James Steel, Dr Christopher Golden
Davy (Joint Broker)
+353 (0) 1 679 6363
Anthony Farrell, Niall Gilchrist
Walbrook PR (Financial PR & IR)
Paul McManus / Alice Woodings /
Lianne Applegarth
+44 (0)20 7933 8780 or hvivo@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407 804 654/
 +44 (0)7584 391 303


 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain. 

 

 

Notes to Editors

 

hVIVO plc (Ticker: HVO) is full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

 

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name of PDMR
Yamin Mo Khan
2
Reason for notification
a.
Position/Status
Chief Executive Officer
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
hVIVO plc
b.
LEI
213800VT5KBM7JLIV118
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification Code
Ordinary shares of £0.001 each
ISIN GB00B9275X97
b.
Nature of the transaction
Purchase of Ordinary Shares
c.
Price(s) and volume(s)
No. of Shares
Price
1,100,000
8.9
d.
Aggregated information
- Aggregated Volume
- Price
See above
e.
Date of the transaction
30 May 2025
f.
Place of the transaction
London Stock Exchange, AIM Market (XLON)

 

 

 

 

1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name of PDMR
Stephen Pinkerton
2
Reason for notification
a.
Position/Status
Chief Financial Officer
b.
Initial notification/
Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
hVIVO plc
b.
LEI
213800VT5KBM7JLIV118
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument

 Identification Code
Ordinary shares of £0.001 each
ISIN GB00B9275X97
b.
Nature of the transaction
Purchase of Ordinary Shares
c.
Price(s) and volume(s)
No. of Shares
Price
683,232
8.76
d.
Aggregated information
- Aggregated Volume
- Price
See above
e.
Date of the transaction
30 May 2025
f.
Place of the transaction
London Stock Exchange, AIM Market (XLON)

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
DSHBFLLBEQLFBBQ